Vertex Pharmaceuticals (VRTX) Holder Azimuth Capital Management LLC Raised Stake by $4.77 Million as Market Valuation Rose

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) LogoInvestors sentiment increased to 1.3 in 2018 Q2. Its up 0.15, from 1.15 in 2018Q1. It improved, as 34 investors sold VRTX shares while 176 reduced holdings. 61 funds opened positions while 211 raised stakes. 236.55 million shares or 1.64% more from 232.72 million shares in 2018Q1 were reported. Brown Advisory Inc reported 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). State Treasurer State Of Michigan invested in 75,468 shares. 1,560 were reported by Checchi Advisers Ltd. Trexquant Investment Lp reported 29,379 shares or 0.35% of all its holdings. Exane Derivatives holds 0% or 709 shares in its portfolio. Nuveen Asset Mgmt Ltd Co has invested 0.02% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Sphera Funds Mngmt Ltd reported 0.47% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Panagora Asset Management owns 955,545 shares. Kepos Cap L P, a New York-based fund reported 33,594 shares. Alpha Windward Ltd owns 530 shares. Great West Life Assurance Can reported 216,080 shares or 0.09% of all its holdings. Guggenheim Ltd holds 262,697 shares. Advisor Ltd invested 0.15% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Boston Private Wealth Limited Liability accumulated 13,721 shares or 0.09% of the stock. Timessquare Cap Management Limited Co holds 0.78% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 683,810 shares.

Since June 1, 2018, it had 0 insider buys, and 29 selling transactions for $44.72 million activity. Sachdev Amit sold $9,989 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Thursday, November 15. $715,615 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by Parini Michael. Arbuckle Stuart A also sold $998,580 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, November 5. $22.43M worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares were sold by LEIDEN JEFFREY M. On Friday, June 22 SMITH IAN F sold $680,000 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 4,250 shares. Shares for $1.31 million were sold by Bhatia Sangeeta N..

Azimuth Capital Management Llc increased its stake in Vertex Pharmaceuticals (VRTX) by 97.91% based on its latest 2018Q2 regulatory filing with the SEC. Azimuth Capital Management Llc bought 28,235 shares as the company’s stock rose 17.38% with the market. The institutional investor held 57,072 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $9.70M, up from 28,837 at the end of the previous reported quarter. Azimuth Capital Management Llc who had been investing in Vertex Pharmaceuticals for a number of months, seems to be bullish on the $46.20 billion market cap company. The stock increased 0.75% or $1.34 during the last trading session, reaching $180.79. About 1.10M shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 13.72% since December 1, 2017 and is uptrending. It has underperformed by 1.90% the S&P500.

More notable recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Nasdaq.com which released: “Vertex (VRTX) Hits Fresh High: Is There Still Room to Run? – Nasdaq” on August 30, 2018, also Nasdaq.com with their article: “Spectrum (SPPI) Earnings and Sales Beat Estimates in Q3 – Nasdaq” published on November 09, 2018, Nasdaq.com published: “Why the Earnings Surprise Streak Could Continue for Vertex (VRTX) – Nasdaq” on October 10, 2018. More interesting news about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were released by: Bizjournals.com and their article: “Why Boston and Texas have so many of the best-paying companies in the U.S. – Dallas Business Journal” published on November 28, 2018 as well as Nasdaq.com‘s news article titled: “Perrigo (PRGO) Beats on Q3 Earnings, Cuts View, Shares Down – Nasdaq” with publication date: November 08, 2018.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Ratings Coverage

Among 7 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Vertex Pharmaceuticals had 9 analyst reports since July 26, 2018 according to SRatingsIntel. The stock has “Buy” rating by H.C. Wainwright on Friday, October 26. Raymond James maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Thursday, October 25. Raymond James has “Outperform” rating and $201 target. The stock has “Buy” rating by Citigroup on Monday, July 30. The firm has “Outperform” rating by BMO Capital Markets given on Thursday, October 25. H.C. Wainwright maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Wednesday, November 28. H.C. Wainwright has “Buy” rating and $22000 target. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has “Overweight” rating given on Thursday, July 26 by Morgan Stanley. UBS maintained the shares of VRTX in report on Thursday, July 26 with “Neutral” rating.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.